You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Strategies for Improving Patient Outcomes in Pediatric-Onset Seizures

  • Authors: Anup D. Patel, MD; Joseph Sullivan, MD, FAES; Ingo Helbig, MD; Elaine Wirrell, MD
  • CME / CE Released: 10/31/2023
  • Valid for credit through: 10/31/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    Nurses - 0.75 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of neurologists, including pediatric neurologists and epileptologists, pediatricians, nurses, nurse practitioners, physician assistants, pharmacists, medical geneticists/genetic counselors, and other clinicians who treat patients with epilepsy.

The goal of this activity is for learners to be better able to implement appropriate strategies to improve patient outcomes in pediatric-onset seizures, including genetic testing, appropriate management, and telehealth/telemedicine.

Upon completion of this activity, participants will:

  • Demonstrate improved performance associated with
    • Identification of patients who should undergo genetic testing for developmental and epileptic encephalopathy (DEE)
    • Selection of genetic tests
    • Interpretation of genetic tests for rare epilepsies
    • Utilization of telehealth/telemedicine for patient management
  • Demonstrate greater confidence in their ability to
    • Develop a comprehensive treatment plan for the management of symptoms associated with DEEs that includes accessible care through telehealth and appropriate medical management


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Moderator

  • Anup D. Patel, MD

    Professor of Clinical Pediatrics and Neurology
    The Ohio State University College of Medicine
    Associate Chief Quality Officer
    Nationwide Children’s Hospital
    Columbus, Ohio

    Disclosures

    Anup D. Patel, MD, has the following relevant financial relationships:
    Consultant or advisor for: Neurelis (former)
    Research funding from: Encoded Therapeutics; Stoke Therapeutics

Faculty

  • Joseph Sullivan, MD, FAES

    Murphy Parker Endowed Professorship in Pediatric Epilepsy
    Professor of Neurology & Pediatrics
    Co-Director, PISCES Longitudinal Integrated Clerkship
    University of California San Francisco
    Director, UCSF Pediatric Epilepsy Center of Excellence
    UCSF Benioff Children’s Hospital
    San Francisco, California

    Disclosures

    Joseph Sullivan, MD, FAES, has the following relevant financial relationships:
    Consultant or advisor for: BrightMinds Biosciences; CAMP4 Therapeutics; Epygenix Therapeutics; Jazz Pharmaceuticals, Inc.; Longboard Pharmaceuticals; Marinus Pharmaceuticals, Inc.; Rapport Therapeutics
    Research funding from: Encoded Therapeutics; Longboard Pharmaceuticals; Marinus Pharmaceuticals, Inc.; Neurocrine Biosciences, Inc.; Stoke Therapeutics; Takeda; UCB Pharma, Inc.; Xenon Pharmaceuticals Inc.; Zogenix, Inc.
    Contracted researcher for: Encoded Therapeutics; Longboard Pharmaceuticals; Marinus Pharmaceuticals, Inc.; Neurocrine Biosciences, Inc.; Stoke Therapeutics; Takeda; UCB Pharma, Inc.; Xenon Pharmaceuticals Inc.; Zogenix, Inc.
    Stock options from: Epygenix Therapeutics

  • Ingo Helbig, MD

    Assistant Professor of Neurology
    Perelman School of Medicine
    University of Pennsylvania
    Director of Genomic Science, Epilepsy NeuroGenetics Initiative (ENGIN)
    Philadelphia, Pennsylvania

    Disclosures

    Ingo Helbig, MD, has the following relevant financial relationships:
    Consultant or advisor for: Biogen; Capsida Biotherapeutics; Encoded Therapeutics
    Research funding from: Ambit Biosciences; Encoded Therapeutics
    Patent beneficiary of: Patent beneficiary of: US Patent Application No 62/843,859 (micro-RNA site-blocking oligonucleotides to treat epileptic encephalopathies and neurodevelopmental disorder)

  • Elaine Wirrell, MD

    Professor of Child Neurology and Epilepsy
    Chair
    Divisions of Child and Adolescent Neurology
    Department of Neurology
    Mayo Clinic
    Rochester, Minnesota

    Disclosures

    Elaine Wirrell, MD, has the following relevant financial relationships:
    Consultant or advisor for: Acadia Pharmaceuticals Inc.; Amicus Therapeutics; Biohaven Pharmaceutical, Inc.; Encoded Therapeutics; GRIN Therapeutics; IAMA Therapeutics; Longboard Pharmaceuticals; Neurocrine Biosciences, Inc.
    Research funding from: Marinus Pharmaceuticals, Inc.; SK-Pharma; Stoke Therapeutics; UCB Pharma, Inc.
    Contracted researcher for: Marinus Pharmaceuticals, Inc.; SK-Pharma; Stoke Therapeutics; UCB Pharma, Inc.

Editor

  • Katherine Carpenter, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Katherine Carpenter, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Eisai, Inc. (former)

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Strategies for Improving Patient Outcomes in Pediatric-Onset Seizures

Authors: Anup D. Patel, MD; Joseph Sullivan, MD, FAES; Ingo Helbig, MD; Elaine Wirrell, MDFaculty and Disclosures

CME / CE Released: 10/31/2023

Valid for credit through: 10/31/2024, 11:59 PM EST

processing....

Contents of This Activity

To start this activity, please assess your clinical knowledge by completing the brief survey at the bottom. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Introduction and Unmet Needs in Developmental and Epileptic Encephalopathies: Where Are We Now?

Dr Patel introduces the goals of this activity.
Anup D. Patel, MD

Review of Symptoms and Genetic Basis of Developmental and Epileptic Encephalopathies

Dr Sullivan summarizes the features common DEEs, including seizures and nonseizure symptoms.
Joseph Sullivan, MD, FAES

Genetic Testing for a Precision Diagnosis of Developmental and Epileptic Encephalopathies

Dr Helbig reviews the types of tests available and gives key pointers for interpreting test results.
Ingo Helbig, MD

Genetics in Practice

Dr Wirrell talks about the next steps: actionable etiologies and practical implications of a genetic diagnosis.
Elaine Wirrell, MD

Enhancing Access to Specialty Care via Telemedicine

Dr Patel describes the potential of telemedicine in helping patients and their families access appropriate care.
Anup D. Patel, MD
 

Learning Feedback Questions

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

  • Print